Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine
- 12 September 2024
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 24 (11) , 1107-1117
Abstract
Rimegepant and atogepant, two innovative oral medications for the treatment of migraine, are gaining prominence in the treatment of migraine. However, outside of specialist headache centers, these novel medications remain subjectively underutilized. While multiple rationales exist describing their underutilization, a leading factor is the complexity and clinical flexibility attributed to the individual members of the gepant medication class. This review provides a brief review of the current uses, common adverse events, and potential areas of future clinical innovation attributed to rimegepant and atogepant. A database search for the term 'Rimegepant OR Atogepant' was completed, yielding 240 individual results. Following multiple rounds of assessment that aimed to determine relevance of each individual result, 42 studies were included in the synthesis of this review. Rimegepant and atogepant are exciting medications that demonstrate significant clinical innovation within the field of migraine therapy. While current indications are clear, data is lacking regarding the future expanded roles of these medications. Current areas of potential therapeutic innovation for rimegepant and atogepant include the pediatric population, in pregnancy and breastfeeding, in cluster headache and post-traumatic headache, and in patients that previously discontinued calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) therapy.Keywords
This publication has 73 references indexed in Scilit:
- Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective ModelClinical Drug Investigation, 2024
- Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective StudyNeurology and Therapy, 2024
- Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical TrialNeurology and Therapy, 2023
- Unmet Needs in the Acute Treatment of MigraineAdvances in Therapy, 2023
- Advances in the Acute and Preventive Treatment of Pediatric MigraineCurrent Pain and Headache Reports, 2023
- A Brief Review of GepantsCurrent Pain and Headache Reports, 2023
- Rimegepant: A Review in the Acute Treatment and Preventive Treatment of MigraineCNS Drugs, 2023
- Gepants — a long way to cure: a narrative reviewNeurological Sciences, 2022
- Comparison of New Pharmacologic Agents With Triptans for Treatment of MigraineJAMA Network Open, 2021
- Rimegepant: First ApprovalDrugs, 2020